J&J to Invest $55B in United States to Boost Manufacturing, R&D

Zacks
03-24

J&J JNJ announced plans to invest more than $55 billion in the United States over the next four years to boost manufacturing, R&D and technology in the country.  This represents a 25% increase in investment compared to the previous four years. J&J believes that the U.S. economic impact of the increased U.S. investment will exceed $100 billion a year.

The investments begin with the groundbreaking of a high-tech 500,000-square-foot, state-of-the-art biologics manufacturing facility in North Carolina.  J&J expects this facility to create 5,000 construction jobs and more than 500 permanent positions once operational.

In addition, the company will build three new advanced manufacturing facilities and expand several existing plans across its Innovative Medicine and MedTech businesses. The locations of the three facilities were not disclosed.

J&J’s shares have outperformed the industry year to date. The stock has risen 13.1% compared with 6.3% growth of the industry.


Image Source: Zacks Investment Research

J&J Follows LLY in Boosting U.S. Investments Amid Tariff Threats

Drugmakers are looking to ramp up U.S. investments after reports that Trump plans to impose tariffs on imports of pharmaceutical products in a bid to encourage domestic production.

Last month, Eli Lilly LLY announced plans to invest $27 billion in building four new manufacturing sites in the United States by 2025, bringing its total domestic manufacturing expansion commitments since 2020 to over $50 billion. The increased manufacturing investment can boost production capacity for Lilly’s medicines, particularly its popular GLP-1 products, Mounjaro and Zepbound.

Pfizer PFE may be the next in line to make a similar announcement. Earlier this month, the company’s chief executive officer (CEO) Albert Bourla, at a healthcare conference, said that Pfizer is prepared to move some of its overseas manufacturing to the United States amid the tariff threats.

J&J’s Zacks Rank

J&J has a Zacks Rank #3 (Hold) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Johnson & Johnson Price and Consensus

Johnson & Johnson price-consensus-chart | Johnson & Johnson Quote

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Johnson & Johnson (JNJ) : Free Stock Analysis Report

Pfizer Inc. (PFE) : Free Stock Analysis Report

Eli Lilly and Company (LLY) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10